Skip to main content

Table 4 A comparison of the performance of conventional biomarkers vs. tenascin-C to predict the escalation of glucocorticoids in patients with SLE

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

Cox model

Variable

Continuous

AIC

C3

C4

Anti-dsDNA

Anti-nucleosome

Tenascin

 AIC

 

165.02

163.52

162.67

161.87

160.40

 C3

165.02

1.000

0.220

0.125

0.076

0.032

 C4

163.52

0.220

1.000

0.357

0.199

0.078

 Anti-dsDNA

162.67

0.125

0.357

1.000

0.370

0.132

 Anti-nucleosome antibodies

161.87

0.076

0.199

0.370

1.000

0.227

 Tenascin

160.40

0.032

0.078

0.132

0.227

1.000

Categorical

 

Low C3

Low C4

Anti-dsDNA+

Anti-nucleosome+

Tenascin+

 AIC

 

165.45

164.44

163.21

160.25

160.06

 Low C3

165.45

1.000

0.314

0.134

0.023

0.020

 Low C4

164.44

0.314

1.000

0.268

0.041

0.036

 Anti-dsDNA antibodies+

163.21

0.134

0.268

1.000

0.085

0.076

 Anti-nucleosome antibodies+

160.25

0.023

0.041

0.085

1.000

0.667

 Tenascin+

160.06

0.020

0.036

0.076

0.667

1.000

  1. anti-dsDNA anti–double-stranded DNA
  2. This table compares univariate Cox regression models to predict the escalation of therapy by glucocorticoids based on the Akaike information criterion (AIC). The lower the value of the AIC, the better the fit of the model. Predictors are treated in the upper part of the table as continuous variables and in the lower part of the table as categorical variables. Paired comparisons of the quality of each model are illustrated by their respective p values. The thresholds for conventional biomarkers were reference values, and a cutoff value of 654 ng/ml for tenascin-C was generated using receiver operating characteristic curve analysis to find the optimal discriminatory threshold to identify patients who would require escalation of glucocorticoids. Boldface type indicates statistically significant values